EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSSTOG00000009320
Gene Symbol: CACNA1E
3 Cross references
294 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSSTOG00000023000
Gene Symbol: CACNA1F
4 Cross references
178 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSSTOG00000019651
Gene Symbol: CACNA1G
4 Cross references
196 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSSTOG00000028353
Gene Symbol: CACNA1H
2 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSSTOG00000025056
Gene Symbol: CACNA1I
3 Cross references
264 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSSTOG00000004823
Gene Symbol: CACNA1S
3 Cross references
259 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSSTOG00000020390
Gene Symbol: CNR1
3 Cross references
205 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSSTOG00000011946
Gene Symbol: CNR2
4 Cross references
191 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSSTOG00000013359
Gene Symbol: CA1
4 Cross references
285 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSSTOG00000016051
Gene Symbol: CA12
4 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSSTOG00000013348
Gene Symbol: CA13
3 Cross references
288 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSSTOG00000027815
Gene Symbol: CA14
3 Cross references
210 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).